Business, energy, technology, markets and global industry news from Business News Today

HARMONi-3

PharmaDeviceNews HARMONi-3
Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.
Pharma & Biotech

Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab

Summit Therapeutics and Lunit will study AI-derived tumor biomarkers for ivonescimab, while clinical validation and patient-selection benefits remain unproven.

Read More
Summit Therapeutics enters a pivotal phase for ivonescimab as the oncology developer deploys its $690.7 million cash position toward an upcoming FDA decision, HARMONi-3 data and an expanding late-stage lung cancer programme. Representative image.
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More